AllAnalyst Report
logoMorningstarMay 06, 2021

Coloplast A/S: Coloplast Faces Pandemic-Driven Disruption to Patient Flow; No Change to Our Fair Value Estimate

Symbols
CLPBY
Sector(s)
Healthcare
Rating
Current Price
$15.97
Fair Value
Economic Moat
Stewardship
Summary

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy-care systems, disposable containment devices, paste, powder, seals, and wipes. Coloplast also maintains a tertiary presence in the urology and wound-care markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

Debbie Wang

Senior Equity Analyst
Debbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.